Novel Therapies in High-Risk Non-Muscle Invasive Bladder Cancer

The management of high-risk non-muscle-invasive bladder cancer(NMIBC) presents a significant challenge to many physicians, due to the ability of the disease to resist intravesical BCG therapy and the substantial rate of progression to the muscle-invasive bladder cancer. In the current literature, the alternative treatment modality for patients with BCG-unresponsive bladder cancer is radical cystectomy, which [...]